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Background: The Menopause Rating Scale is a health-related Quality of Life scale developed in
the early 1990s and step-by-step validated since then. No methodologically detailed work on the
utility of the scale to assess health-related changes after treatment was published before.
Method: We analysed an open, uncontrolled post-marketing study with over 9000 women with
pre- and post-treatment data of the MRS scale to critically evaluate the capacity of the scale to
measure the health-related effects of hormone treatment independent from the severity of
complaints at baseline.
Results: The improvement of complaints during treatment relative to the baseline score was 36%
in average. Patients with little/no complaints before therapy improved by 11%, those with mild
complaints at entry by 32%, with moderate by 44%, and with severe symptoms by 55% – compared
with the baseline score. We showed that the distribution of complaints in women before therapy
returned to norm values after 6 months of hormone treatment. We also provided weak evidence
that the MRS results may well predict the assessment of the treating physician. Limitations of the
study, however, may have lead to overestimating the utility of the MRS scale as outcome measure.
Conclusion: The MRS scale showed some evidence for its ability to measure treatment effects on
quality of life across the full range of severity of complaints in aging women. This however needs
confirmation in other and better-designed clinical/outcome studies.
Background
The Menopause Rating Scale (MRS) was initially devel-
oped in the early 1990s [1,2] to measure the severity of
age-/menopause-related complaints by rating a profile of
symptoms.
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The validation of the MRS began some years ago [2-6]
with the objectives (1) to enable comparisons of the
symptoms of aging between groups of women under dif-
ferent conditions, (2) to compare severity of symptoms
over time, and (3) to measure changes pre- and post-treat-
ment [4-6].
Development and standardization of the scale were pub-
lished elsewhere [2]. In brief, the standardization of this
scale was performed on the basis of a representative sam-
ple of 500 German women aged 45–60 years in 1996. A
factorial analysis was applied to establish the raw scale of
complaints or symptoms. Statistical methods were used to
identify the dimensions of the scale. Finally, three dimen-
sions of symptoms/complaints were identified: a psycho-
logical, a somatic-vegetative, and a urogenital factor that
explained 59 % of the total variance [2]. This is indicative
for a high efficiency of a scale with only 11 items – com-
pared to other international scales. Reference values for
the severity of symptoms or complaints were calculated
based on a population sample [2]. The scale consisting of
11 items is self-completed by the woman. A 5-point rating
scale permits to describe the perceived severity of com-
plaints of each item (severity 0 [no complaints]...4 scoring
points [very severe symptoms]) by checking the appropri-
ate box. The composite scores for each of the dimensions
(sub-scales) are based on adding up the scores of the items
of the respective dimensions. The composite score (total
score) is the sum of the dimension scores. Details as how
to apply and evaluate the scale were published [8,9] and
can be also obtained from the website http://www.meno
pause-rating-scale.info.
The scale was defined as a menopause-specifc, health-
related quality of life scale (HRQoL), because the profil of
complaints in this scale importantly determines the
HRQoL of women in this age span. Moreover, a good cor-
relation between the results obtained with the MRS scale
and the generic QoL scale was observed [6].
The MRS scale became internationally well accepted as far
as the usage many countries is concerned. The first trans-
lation was into English [7]. Other translations followed
[8], i.e. taking international methodological recommen-
dations [10-12] into consideration. Currently, the follow-
ing versions are available: Brazilian, English, French,
German, Indonesian, Italian, Mexican/Argentine, Span-
ish, Swedish, and Turkish language. These versions are
available in a published form, and can be downloaded in
PDF-format from the internet (see reference 8 and http://
www.menopause-rating-scale.info).
Like in other health-related QoL scales, it is a challenge to
satisfy the demands of a clinical utility and outcomes sen-
sitivity. A comprehensive overview regarding conven-
tional psychometric requirements of test reliability and
validity were recently published elsewhere [9]. It is the
aim of this paper is to share methodological information
about the capacity of the scale to assess changes after hor-
mone treatment since no methodologically detailed work
in this regard was published before.
Methods
A multicenter, open post-marketing study was conducted
with a product for hormone therapy (CLIMEN® = 2 mg
estradiol valerate/2 mg estradiol valerate + 1 mg cyproter-
one acetate) using the MRS scale as outcome measure
under routine conditions of office-based gynaecologists.
The study was described in detail elsewhere [6].
In brief, 1801 gynaecologists from all parts of Germany
participated in the study on a voluntary basis. 10,904
women who required hormone treatment were included.
The median age was 49 years. Beside others, the MRS scale
was documented before therapy and 6 months after start-
ing the hormone treatment.
A specific problem was the transformation of an older
MRS version into the advanced, relatively broad validated
current version of MRS. The old version of the MRS was
read by the physician and the patient answered to which
extend she perceived suffering from a specific symptom,
and if yes to which extend. The new scale is self-completed
by the woman without interaction with the physician. The
symptoms itself are the same in both scales. Nevertheless,
this is a methodological limitation. We, however, are not
interested in the absolute score values but relative changes
after treatment compared to before. In addition, the scor-
ing system of the old version was adjusted into the new
coding system using a linear transformation. Addition-
ally, one question of the old version was split into two
questions – as recommended for the current version of the
MRS (see later discussion on limitations of the study).
The statistical analyses were performed with the commer-
cial statistical package SAS 8.2.
Results
Altogether, data of 9311 women were available for most
of our analysis. However, the sample size varied slightly
depending on the variables used because we had also
missing information in a few variables.
The mean age was 49.8 years (SD 6.4). About half of the
participating women were still perimenopausal (51.9%)
or were already in the postmenopausal phase (48.1%).
The mean body mass index was not eye-catching with
24.7 (SD 3.7).Health and Quality of Life Outcomes 2004, 2:67 http://www.hqlo.com/content/2/1/67
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The improvement of the health-related quality of life
(HRQoL) – measured with the MRS scale – is described in
Table 1. The means and SD of the scoring points of the
total scale (and the three subscales) can be seen at base-
line (before therapy) and after six months of hormone
treatment. Significant declines of the mean scores were
observed after treatment indicating an improvement of
HRQoL altogether and in the three subscales of the MRS.
Apart from the comparison of means, we calculated the
relative improvement compared with the situation before
therapy (baseline) to better understand the magnitude of
change after therapy (Table 1), i.e. in absolute and relative
terms. There was not much difference in relative improve-
ment (%) among subscales (all highly significant): In
average, the scores improved by one third after six months
hormone treatment.
The scale is able to measure an improvement in patients
starting with "no/little complaints" (total score = 0–4),
"mild" (5–8), "moderate"(9–15), and "severe" (16 +
points) before therapy (= baseline). This is presented in
Table 2: The more severe the complaints were before treat-
ment the better the effect regarding relative improvement
of symptoms measured by the MRS, which gives evidence
for the clinical utility of the MRS as outcome measure.
It is interesting to compare the HRQoL before and after
hormone treatment with the norm values of MRS
obtained in an average population of aging women, i.e.
not patients as in our post-marketing study. To this end,
we compared only the MRS total scores in patients with
the average female population (Table 3). It became evi-
dent in this crude and simple comparison, that the
severely deteriorated distribution of complaints in the
patient group before therapy – compared with the normal
population – improved after therapy remarkable, i.e., at
least as far as the total score of the MRS is concerned. The
three subscales showed a similar tendency towards the
better. The extremely high proportion of patients without
complaints immediately after therapy could be due to a
selection problem in this post-marketing study and the
application of the physician-administered version of the
MRS (see discussion).
The treating gynaecologist (who also applied the MRS
scale) assessed individually the efficiency of the hormone
treatment in the above mentioned intervention study. The
gynaecologist's expert opinion regarding treatment effi-
ciency was categorized into two categories for the purpose
of this analysis: successful (very effective and effective) and
not successful (little, no, or negative effects). This alterna-
tive variable was then used for the comparison with the
Table 1: Means (SD) of MRS scores at baseline (before therapy) and at end of observation (after therapy. Improvement of scores after 
therapy by absolute difference in scoring points. §Total scale and for each subscale.
n Scores before Scores after Absolute change Percent (%) change P**
Total scale 9311 11.0 (8.2) 1.7 (3.2) 9.3 (7.4) 36.1 (20.6) <0.0001
Psychological subscale 9311 4.5 (4.1) 0.7 (1.7) 3.8 (3.7) 34.5 (27.1) <0.0001
Somatic subscale 9311 4.2 (3.2) 0.5 (1.2) 3.6 (3.0) 37.3 (23.1) <0.0001
Urogenital subscale 9311 2.3 (2.6) 0.5 (1.1) 1.8 (2.3) 24.5 (25.3) <0.0001
§ Summary score "before therapy" minus "after therapy"
* Percent (%) change compared with the change before treatment: pre-treatment score minus post-treatment divided by pre-treatment score 
multiplied by 100 (%)
** Paired t-test for dependent samples: significance of the absolute difference
Table 2: Relative change of MRS scoring points as percent of the baseline total score: Mean values (SD) of the relative change (% 
improvement of the complaints) in four categories of severity at baseline.
Severity of complaints at baseline
No/little (0–4) Mild (5–8) Moderate (9–15) Severe (16+)
Means (SD) (n = 2460) Means (SD) (n = 1693) Means (SD) (n = 2592) Means (SD) (n = 2566)
Total score 10.8 (10.6) 32.2 (9.8) 43.9 (11.8) 55.1 (13.8)
Psychological score 6.0 (14.7) 27.6 (21.5) 43.7 (20.6) 57.1 (17.9)
Somatic score 13.8 (17.3) 34.4 (18.5) 44.1 (16.9) 54.8 (15.9)
Urogenital score 5.7 (13.9) 17.0 (20.6) 27.5 (23.6) 44.4 (22.6)Health and Quality of Life Outcomes 2004, 2:67 http://www.hqlo.com/content/2/1/67
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alternative "success-variable" based on MRS (total score
only): "successful" (5 and more points reduction after ther-
apy compared with baseline test) and "not successful" (less
than 5 scoring points reduction after therapy compared
with baseline test).
The prediction of the expert opinion of the treating gynae-
cologist with the MRS data seems to be good: sensitivity
(correct prediction of a positive assessment by the physi-
cian) 70.8% and specificity (correct prediction of a nega-
tive assessment by the physician) 73.5% (Table 4).
Discussion
The MRS scale was developed (a) to assess symptoms of
aging/menopause (independent from those that are dis-
ease-related) or HRQoL between groups of women under
different conditions, (b) to evaluate the severity of symp-
toms over time, and (c) to measure changes pre- and post
hormone replacement therapy. The aim of this paper was
to empirically demonstrate that the latter claim is evident.
Reliability and validity are important to show the useful-
ness of the scale as a clinical utility in monitoring treat-
ment effects – once all other methodological
requirements are successfully demonstrated before. Relia-
bility measures (internal consistency and test-retest stabil-
ity) were found to be good across countries [9]. Regarding
validity it was shown that the internal structure of the MRS
across countries was sufficiently similar to conclude that
the scale really measures the same phenomenon [9].
Table 3: Level of complaints in the population in percent (%) compared with patients of the Climen treatment study: Frequency 
distribution before/after therapy compared with population norm values*
Frequency in patients: Percent (%)in four categories of severity
Severity of complaints Population % Standard Before therapy % After therapy %
Total score
No or little (-4) 48 26.4 86.8
Mild (5–8) 25 18.2 8.4
Moderate (9–15) 20 27.8 4.0
Severe (16+) 8 27.6 0.8
Psychological score
No or little (-1) 48 30.7 82.5
Mild (2–3) 23 17.0 10.4
Moderate (4–6) 20 22.2 5.5
Severe (7+) 9 30.1 1.6
Somatic score
No or little (-2) 53 35.7 93.0
Mild (3–4) 24 22.7 5.1
Moderate (5–7) 15 25.5 1.6
Severe (8+) 8 16.1 0.3
Sexual score
No or little (0) 64 37.3 76.8
Mild (1) 13 13.3 11.6
Moderate (2–3) 16 22.2 8.7
Severe (4+) 7 27.3 2.9
* The population data came from the standardization of the MRS scale [2,3]
Table 4: Prediction of a positive assessment by the physician concerning "successful treatment" by means of the MRS scale (total 
score)."Not successful" was defined for the MRS as: less than 5 scoring points improvement at the end of the HRT treatment compared 
with "before treatment".
MRS: not successful MRS: successful Total
Doctor: not successful 311 112 423
Doctor: successful 2570 6227 8797
Total 2881 6339 9220
Sensitivity: 70.8%
Specificity: 73.5Health and Quality of Life Outcomes 2004, 2:67 http://www.hqlo.com/content/2/1/67
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The comparison with another scale for aging women –
although not a validated HRQoL scale (Kupperman) –
showed sufficiently good correlations of the total score,
which is compatible with the notion of a good criterion-
oriented validity. The same is true for the comparison
with the generic quality-of-life scale SF36 where also high
correlation coefficients have been shown [3-5]. Another
fact in favor of the scale is that it was translated into 10
languages so already [7-9].
Having the above-mentioned psychometric data availa-
ble, a point was reached to critically evaluate the capacity
of the scale to reliably measure health-related effects of
hormone treatment independent from the severity of
complaints and – in addition – to the comparison of treat-
ment effects measured by the MRS scale and the subjective
assessment by the treating physician. To this end, many
clinicians use the term "validity" and mean high utility for
clinical work or research.
The only hormone treatment study with the MRS scale as
outcome measure in women during menopausal transi-
tion we could get data for methodological analysis was the
above described postmarketing study. We hope to repeat/
confirm this analysis with data of a more stringently
designed clinical trial. But even on the basis of a method-
ologically weak dataset, in absence of other data, we got
re-assuring methodological information about the MRS
scale.
It is a well-established experience that women with men-
opausal complaints respond to hormone therapy with a
marked improvement of the HRQoL. This is what the
MRS scale should be able to detect.
We saw that the increased mean MRS total score at base-
line (before treatment) markedly decreased after 6
months under treatment indicating a significant improve-
ment of complaints & HRQoL. This was also the case for
the mean scores of the three subscales. These data cannot
disentangle the effect of treatment and "natural variation"
of complaints over time. This however was not the point:
It was not the intention of this paper to evaluate effective-
ness of hormone therapy in an uncontrolled post-market-
ing study.
The absolute improvement of symptoms during treat-
ment was 9.3 points of the MRS total score on average.
This is equivalent to 36% of the baseline score, and simi-
lar also for all three subscales. In other words, the MRS
scale was shown to be successful in detecting treatment
effects. The impressive magnitude of the therapy-related
improvement of HRQoL should be obviously discussed in
the context of selection of women with complaints sus-
ceptible for this kind of treatment by the participating
gynaecologists. Another critical remark is that we cannot
comment as to what extend the MRS scale is able to meas-
ure true or placebo treatment effects. But this is more a
question concerning efficacy and the study draw any con-
clusions in this regard by definition of the study design.
To answer the question whether the sensitivity of the MRS
scale is good enough to detect even treatment-related
changes in women with only little or mild symptoms as
compared with severe ones, the analysis was stratified. An
improvement of complaints/QoL was seen in an increas-
ing degree in patients with little, mild, moderate and
severe symptoms at baseline. The relative improvement
increased with the degree of severity of symptoms at base-
line, which is consistent with the general expectation. It
seems to be important to underscore: The MRS scale
seems to detect also a positive treatment effect in women
with little complaints – although to a lesser degree.
Moreover, we showed the capacity of the MRS scale to
determine therapeutic efficiency with another approach: a
face-value-comparison with norm values of the popula-
tion [2,3]. The level of complaints in patients before ther-
apy expressed a higher degree of severity (higher MRS
total score). After 6 months of hormone treatment the fre-
quency distribution of patients with a certain severity of
complaints returned towards a similar distribution as
observed in the general population. The extreme propor-
tion of patients with no/ little complaints after therapy
should be again seen in the context of apparent patient
selection (patients were not only treated because of their
symptoms but also for other indications such as preven-
tion) and/or effects of the interaction of patients with the
treating physician (who also administered the MRS. Thus,
we cannot exclude that such a biases have inflated the
impression of a "too positive therapy efficiency". But we
do not intent to draw conclusions about therapeutic effi-
ciency anyway. It is another way to look at therapeutic
efficiency with the assistance of the MRS scale. Although
this indicates at least that comparisons with norm values
could be helpful for interpreting results of intervention
studies, we are not recommending formal statistical test-
ing of differences between patient groups and the refer-
ence values of the population: Patients are usually too
different from the general population, a difference hard to
adjust for. It is just a visual comparison (as in Table 3) to
get a crude idea for the interpretation of results.
The MRS scale was also tested whether it predicts the ther-
apeutic assessment of the treating physician. At face value,
the individually assessed efficiency of hormone treatment
by the treating gynaecologists was comparable with the
assessment by the MRS scale, i.e. using a simple dichot-
omization of the treatment effect in "successful" and "not
successful" for both the subjective opinion of the physicianHealth and Quality of Life Outcomes 2004, 2:67 http://www.hqlo.com/content/2/1/67
Page 6 of 7
(page number not for citation purposes)
and the result of the MRS scale: The sensitivity (correct
prediction of a positive assessment by the physician) was
70.8% and specificity (correct prediction of a negative
assessment by the physician) 73.5%. In other words, the
MRS scale fits well with the subjective assessment of the
treatment effect estimated by the physician. However,
conclusions have to be drawn very carefully because of a
possibly inherent bias that may have inflated the positive
result: The subjective assessment of "success" by the treat-
ing physician was obviously not as independent from the
assessment by the MRS scale as desirable because the phy-
sician applied the scale to the patient. Even without being
able to recall the result of the MRS six month ago or to cal-
culate and compare the total score of both administra-
tions, the interaction with the patients is likely to have
introduced this bias in the direction of a higher compati-
bility between both assessments.
Although the result may too positive compared with a
blinded, really independent assessment, it permits to gen-
erate the working hypothesis of a sufficiently good predic-
tion of the therapeutic effect by means of the MRS scale.
This needs to be confirmed with better data, i.e. data from
a blinded, independent comparison, i.e. with the cur-
rently used, self-administered MRS scale.
The aim of this exercise was only to demonstrate that the
MRS scale may well predict the clinical opinion about effi-
ciency of hormone therapy, what was not empirically
shown before. We recommend the MRS as standardized/
validated "objective" scale for use in clinical studies,
although some aspects discussed above need confirma-
tion in a new study. Moreover, since the scale is already
broadly used at the international level, it is important to
sensitise users about some lacking information or weak
evidence.
The limitations of this study should be shortly summa-
rized. First of all, this study was performed in a dataset
where an earlier version of the MRS scale was used, i.e. the
scale was not self-administered but completed in an inter-
view of the physician with the patient. This could have
influenced the magnitude of the absolute scores of the
total and sub-scales. As far as pre-/post-treatment changes
are concerned, the magnitude of the absolute changes
may have been more influenced than the relative changes
of the HRQoL assessment of the patients as discussed in
this paper. Another problem along the same line is that we
had to transform the old coding system into the new one.
This was done with a simple linear transformation and is
not likely to have introduced any bias. Another limitation
is that this is the first study we are aware of for this kind of
assessment of the validity to measure therapeutic
intervention.
It is not likely that the main conclusions of the study are
materially biased. However, the results should be cau-
tiously used (e.g., for planning clinical trials or outcomes
studies) as long as not confirmed with data obtained with
the currently used self-administered MRS scale without
potential influence of the physician. It can be assumed
that a new study with the currently recommended MRS
scale – in the sense of "patient-reported-outcome" –
would demonstrate positive results but to a lesser degree.
Conclusions
The MRS scale showed some evidence for its ability to
measure treatment effects on quality of life across the full
range of severity of complaints in aging women. This how-
ever needs confirmation in other and better-designed clin-
ical studies.
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